Change in height · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in BMI · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of bowel symptoms: stool frequency · adults and children with cystic fibrosis
1 finding from 1 review
CFA: FFE (g/day) · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall mortality · alcohol consumers with high blood pressure
The intervention showed no clear difference in overall mortality (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular events · alcohol consumers with high blood pressure
It is very uncertain whether the intervention changes cardiovascular events (very low certainty).
1 finding from 1 review
Intervention not reported
Decrease in systolic blood pressure (mmHg) · alcohol consumers with high blood pressure
1 finding from 1 review
Intervention not reported
Decrease in diastolic blood pressure (mmHg) · alcohol consumers with high blood pressure
1 finding from 1 review
Intervention not reported
Decrease in alcohol intake (g) · alcohol consumers with high blood pressure
1 finding from 1 review
Intervention not reported
Proportion of subjects with SBP < 140 mmHg and DBP < 90 mmHg · alcohol consumers with high blood pressure
It is very uncertain whether the intervention changes proportion of subjects with SBP < 140 mmHg and DBP < 90 mmHg (very low certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower CVD compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in all‐cause mortality compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in myocardial infarction compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in any stroke compared with ezetimibe and statins (low certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes CVD compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes all‐cause mortality compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes myocardial infarction compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
1 finding from 1 review